Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting

Autor: Acceleron Pharma Inc.
Zdroj: Business Wire (English). 11/04/2020.
Abstrakt: Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that data from six clinical abstracts on REBLOZYL (luspatercept-aamt) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition held virtually December 5-8, 2020. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje